2021 Online, In the cloud

II-33 Marcus Baaz
Evaluation and Optimization of Model-based Translations in Oncology - From Xenografts to RECIST
II-35 Elisa Borella
PKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population
II-36 Aurore CARROT
Population K-PD modelling of PSA kinetics in patients with recurrent prostate cancer.
II-37 Marc Cerou
A model-based approach to evaluate the effect of isatuximab in combination with pomalidomide and dexamethasone using multiple composite endpoints: Application to the ICARIA study in relapsed/refractory multiple myeloma
II-38 Pascal Chanu
A disease model for Multiple Myeloma developed using Real World Data
II-39 Jonathan Chauvin
A library of tumor growth and tumor growth inhibition models for the MonolixSuite
II-40 Wan-Yu Chu
Elucidating the effect of platelet binding on vincristine distribution by a physiologically based pharmacokinetic (PBPK) approach
II-41 David Damoiseaux
Predictiveness of the human CYP3A4 transgenic mouse model (Cyp3aXAV) for human drug exposure assessed using a population pharmacokinetic approach
II-42 Nikki de Rouw
Costs of pemetrexed-associated neutropenia and the budget impact of pemetrexed dose individualization
II-43 Carlos Fernandez-Teruel
Population Pharmacokinetics of Capivasertib, a Potent Selective AKT Inhibitor, in Patients with Solid Tumours
II-44 David Hodson
Non linear mixed effects modelling of tumour interactions with the adaptive immune response during Radiotherapy in combination with anti-PDL1 or Olaparib.
II-45 Eman Ibrahim
Pharmacokinetic-pharmacodynamic (PK-PD) modeling of leukocyte dynamics and lymph node size in chronic lymphocytic leukaemia patients treated with ibrutinib
II-46 Itziar Irurzun Arana
Ceralasertib-induced haematological toxicity modelling to support monotherapy Recommended Phase 2 Dose determination
II-47 Martin Johnson
Long short-term memory recurrent neural networks to predict longitudinal changes in tumour size
II-48 Yoshimasa Kobayashi
Pharmacometric analysis to justify a higher recommended dose for trastuzumab deruxtecan in the treatment of subjects with metastatic gastric cancer versus breast cancer
II-49 Naoki Kotani
A model based approach to infer overall survival (OS) in hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (HR+/HER2- mBC)
II-50 Nataliya Kudryashova
The Markov chain survival modeling platform for cancer burden assessment
II-51 Rachael Lawson
Development of a time dependent clearance model for busulfan in paediatric patients to investigate dosing adjustment scenarios
II-52 Xia Li
Population-based Target-Mediated Drug Disposition (TMDD) Pharmacokinetics Model of Daratumumab in Patients With Multiple Myeloma Following Intravenously Daratumumab Monotherapy
II-53 Sarah Lobet
Target-mediated pharmacokinetics of cetuximab: target occupancy influences progression-free survival
II-54 Paolo Magni
Reduced food-intake and sarcopenia in animal models of cancer anorexia-cachexia syndrome: a Dynamic Energy Budget (DEB)-based modeling approach
II-55 Luca Marzano
Role of tree-based machine learning algorithms in prognostic pattern detection: an Extensive-Disease Small Cell Lung Cancer (ED-SCLC) study
II-56 Zinnia Parra-Guillen
Mechanistic modeling of a novel oncolytic virus, V937, to describe viral kinetic and dynamic processes following intratumoral and intravenous administration
II-57 Clémence Pouzin
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
II-58 Alicja Puszkiel
Optimisation of the dose and schedule of everolimus and sorafenib combination therapy in patients with solid tumors using a PKPD/time-to-event model
II-59 Thomas RODIER
Population Pharmacokinetic-Pharmacogenetic Analysis of Osimertinib in patients with Non-Small Cell Lung Cancer
II-60 Aymara Sancho
Semi-mechanistic model for the antitumor response of a combination cocktail of immune-modulators in non-inflamed (cold tumors)
II-61 Eduard Schmulenson
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP)
II-62 Gianluca Selvaggio
Computational analysis of cytokine release following bispecific T-cell engager therapy
II-63 Hinke Siebinga
A Population Pharmacokinetic Model to Assess Variability in Pharmacokinetics of 177Lu-PSMA-617 in Low Volume Metastatic Prostate Cancer Patients
II-64 Alexandra Smirnova
Dose dependence of safety of PD-1 and CTLA-4 checkpoint inhibitors: Comparison of normal-normal and binomial-normal hierarchical models for rare events in a Bayesian meta-analysis framework
II-65 Alina Sofronova
The multivariate baseline and longitudinal biomarker analysis for the survival prediction in NSCLC by means of joint modeling
II-66 Xuyang SONG
Population Pharmacokinetics Modeling of Monalizumab in Cancer Patients with Longitudinal Patient/Disease Characteristics
II-67 Maximilian Strobl
Adaptive therapy: Leveraging eco-evolutionary principles to improve resistance management in oncology
II-68 Elena Tosca
A tumor-in-host Dynamic Energy Budget (DEB)-based paradigm for preclinical to clinical translation: predictions of tumor-in-host growth dynamics
II-69 Armando Tratenšek
Target-mediated drug disposition model of rituximab in patients with diffuse large B-cell lymphoma
II-70 Van Thuy Truong
A comparison of ordinary differential equation and agent-based approaches to PKPD modelling in oncology
II-72 Maarten Van Eijk
Pharmacokinetic and pharmacodynamic modelling of different oral paclitaxel formulations co-administered with ritonavir.
II-73 Elena Vasileva
Pharmacokinetic, receptor occupancy and pharmacodynamic (PK/RO/PD) modeling of ALX148, a CD47 blocker